Skip to content

Author

M. Mamas

We have 10 of 128 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jan 2026

Clinical Significance of Time in Therapeutic Range (TTR) During Unfractionated Heparin Therapy in Non-ST-Segment Elevation Myocardial Infarction

Background Unfractionated heparin (UFH) is widely used in non-ST-segment elevation myocardial infarction (NSTEMI), but its narrow therapeutic window requires frequent activated partial thromboplastin time (aPTT) monitoring. Data on time in therapeutic range (TTR) in this setting are scarce. Methods We analyzed 1,553 co...

Tal Golani, L. Taha, M. Karmi et al. · 0 citations
Open access Oct 2026

Physician Sex and Outcomes Among Hospitalized Patients

This cohort study evaluates differences in mortality and hospital readmission outcomes among adult hospitalized patients treated primarily by female compared with male physicians in Canada.

Angela Jerath, Christopher J. D. Wallis, K. Heybati et al. · 0 citations
Open access Aug 2026

The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023

Summary Background The cardiovascular-kidney-liver-metabolic (CKLM) framework represents the multi-organ interplay of systemic metabolic disorders that drive the global burden of cardiovascular diseases (CVD). Methods This study is a descriptive epidemiological analysis of the Global Burden of Disease Study 2023 that e...

J. Jayabaskaran, Haryo Raden Himan, S. Nagarajan et al. · 0 citations
Review Open access Aug 2026

Machine learning—enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality

Abstract Aims Cancer therapy-related cardiac dysfunction (CTRCD) is a prevalent complication with adverse clinical implications. Guidelines have emphasized the need for reliable baseline risk prediction to guide prevention strategies. While machine learning (ML) has shown promise in cardiovascular medicine, the readine...

M. Andres, Vijay Maharahan, Alexandra Pons Rivarola et al. · 0 citations
Review Open access Aug 2026

Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions

Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atheroscl...

P. Sabouret, Domenico Mario Giamundo, J. Popiołek-Kalisz et al. · 0 citations
Aug 2026

Pre-existing cardiovascular disease at cancer diagnosis: national trends and future projections in england

The burden of pre-existing CVD at cancer diagnosis has increased substantially over the past two decades in the UK and is projected to rise further, highlighting the growing need for integrated prevention strategies and cardio-oncology services to address increasing multimorbidity in patients with cancer.

A. Alshahrani, E. Kontopantelis, C. Morgan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.